Sanofi Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Sanofi
See the Bigger Picture
Sanofi’s BCG Matrix snapshot highlights a mix of established Cash Cows from its mature vaccine and chronic care franchises, emerging Stars in specialty therapies, and potential Question Marks in niche biologics facing competitive pressure—insightful for allocating R&D and capital efficiently. This preview teases quadrant placements and strategic implications; purchase the full BCG Matrix for a complete, data-backed breakdown, actionable recommendations, and ready-to-use Word and Excel deliverables to guide investment and product decisions.
Stars
Dupixent (Dupilumab)
As of end 2025, Dupixent (dupilumab) is Sanofi’s premier Star, delivering €15.7 billion in 2025 sales and sustaining >25% annual growth.
It holds dominant market share in atopic dermatitis and asthma and is expanding into COPD and chronic spontaneous urticaria with multiple Phase III readouts in 2024–2025.
Dupixent generates massive cash but needs continued investment in label expansion and global commercialization to defend against emerging biologics and biosimilars.
ALTUVIIIO (Hemophilia A)
ALTUVIIIO (rFVIII, Hemophilia A) reached blockbuster status by end-2025 with €1.2 billion in annual sales and quarterly growth spikes over 90%, reflecting rapid uptake since launch.
The once-weekly extended half-life factor VIII has taken market share from conventional FVIII products by improving dosing frequency and adherence, driving estimated global share above 20% in 2025.
As a Star in Sanofi’s BCG matrix, ALTUVIIIO still requires heavy promotional spend—R&D and commercial investment remained high in 2025 to cement its standard-of-care position.
Beyfortus (Nirsevimab)
Beyfortus (nirsevimab) is a Star for Sanofi in vaccines, posting €1.8 billion sales in 2025 and growing fastest in North America and Europe with rollouts in 35+ countries.
It dominates the RSV infant-protection market with first-to-market advantages in many regions and >60% share in hospital-protected infants in 2025.
Sanofi is investing >€1.2 billion through 2026 in manufacturing and global distribution to meet demand and convert Beyfortus toward Cash Cow status.
Ayvakit (Avapritinib)
Acquired in 2025 via Blueprint Medicines deal worth $9.5 billion, Ayvakit (avapritinib) became a Star for Sanofi in rare immunology and oncology by end-2025 with ~ $725 million pro-forma sales, leading systemic mastocytosis in a small but growing market.
Sanofi is funneling heavy investment to scale Ayvakit globally, boost diagnostic awareness, and anchor its hematology franchise, accepting high spend to capture long-term market share and diagnostics-driven uptake.
- 2025 purchase: $9.5B
- 2025 sales: ~$725M pro-forma
- Indication: systemic mastocytosis, high niche share
- Strategy: global rollout, diagnostic education, heavy capex/OPEX
Nexviazyme (Pompe Disease)
Nexviazyme has moved into the Star quadrant by taking share from Myozyme, posting double-digit growth to reach about €790–€810 million in 2024 sales, marking Sanofi’s lead in Pompe disease enzyme replacement therapy.
Sanofi still funds patient-switch programs and ongoing regulatory filings in emerging markets (India, BRICS) to sustain uptake and extend label access, supporting continued high-margin growth.
- 2024 sales ≈ €800M
- Double-digit YoY growth (2023→2024)
- Displaced Myozyme as market leader
- Ongoing switch programs & filings in emerging markets
Biotech Blockbusters: Dupixent €15.7B, Beyfortus €1.8B, ALTUVIIIO €1.2B, growth leaders
Stars: Dupixent €15.7B (2025), >25% CAGR; ALTUVIIIO €1.2B (2025), ~20% global FVIII share; Beyfortus €1.8B (2025), >60% hospital protection share; Ayvakit $725M (pro-forma 2025); Nexviazyme ~€800M (2024), double-digit growth.
| Product | 2024/25 Sales | Key metric |
|---|---|---|
| Dupixent | €15.7B (2025) | >25% CAGR |
| ALTUVIIIO | €1.2B (2025) | ~20% share |
| Beyfortus | €1.8B (2025) | >60% hospital |
| Ayvakit | $725M (2025) | niche leader |
| Nexviazyme | ~€800M (2024) | double-digit growth |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix analysis of Sanofi’s portfolio with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page Sanofi BCG Matrix placing each business unit in a quadrant for swift portfolio decisions
Cash Cows
Lantus (Insulin Glargine)
Lantus (insulin glargine) stays a Cash Cow for Sanofi, delivering stable cash flow in a mature diabetes market despite biosimilar pressure.
In 2025 Lantus saw a temporary windfall from competitor shortages, kept high market share and generated over €1.7 billion in revenue that year.
As a legacy product it needs minimal promotion, letting Sanofi milk profits to fund R&D in immunology and vaccines.
Toujeo (Insulin Glargine 300 U/mL)
Toujeo (insulin glargine 300 U/mL) is a Cash Cow for Sanofi, holding high market share in basal insulin—notably in Rest of the World—driving steady demand with low market growth.
It generates over €1.3 billion annually with high gross margins from established manufacturing and low R&D churn; 2024 margins reported near industry-normal levels.
Cash flows from Toujeo fund Sanofi’s corporate debt service and materially support the €10 billion 2025 share buyback program announced in 2024.
Poliomyelitis and Pertussis Vaccines
Sanofi’s IPV (inactivated poliovirus vaccine) and acellular pertussis combos anchor its pediatric vaccine franchise, holding ~25–30% global market share in a mature market growing ~1–2% annually as of 2025.
These vaccines generate steady, predictable cash flow with low marketing spend—Sanofi reported €2.1bn pediatric vaccine sales in 2024—funding R&D into mRNA and recombinant platforms.
Fabrazyme (Fabry Disease)
Fabrazyme (Fabry disease) is a cash cow for Sanofi, with global annual sales above €1.1 billion as of end‑2025 and a dominant market share in a mature enzyme‑replacement therapy market.
Low incremental R&D and manufacturing needs keep margins high; strong patent protection and complex biologic manufacturing create high barriers to entry, preserving steady cash flow.
Sanofi channels these profits into higher‑risk oncology and neurology programs, funding pipeline spend without major new investment in Fabrazyme.
- 2025 sales: >€1.1 billion
- Mature market: low growth, high profitability
- High barriers: patents + complex biologics manufacturing
- Uses: fund oncology and neurology pipeline
Plavix (Clopidogrel)
Despite patent expiry, Plavix (clopidogrel) stays a Cash Cow for Sanofi in select international markets—notably parts of Asia and Latin America—where brand loyalty and entrenched distribution sustain share.
It still nets nearly €1 billion in annual revenue with minimal operating costs; gross margins exceed 80% in mature markets, supplying steady, low-effort cash flow.
Sanofi channels these passive gains to fund its pivot to a pure-play biopharma, covering R&D investments and M&A financing for specialty assets.
- Annual revenue: ~€1 billion
- Gross margin: >80% in mature markets
- Low operating expense: minimal marketing/production
- Use: funds R&D and biopharma M&A
Sanofi’s 2025 cash cows (Lantus, Toujeo, IPV, Fabrazyme, Plavix) drive €6.2–6.5bn
Lantus, Toujeo, IPV/pertussis, Fabrazyme, and Plavix are Sanofi Cash Cows in 2025, together generating roughly €6.2–6.5bn in annual revenue and funding R&D, debt service, and a €10bn buyback program.
| Product | 2025 rev (€bn) | Market growth | Role |
|---|---|---|---|
| Lantus | 1.7+ | 0–1% | Fund R&D |
| Toujeo | 1.3+ | 0–1% | Debt/buybacks |
| IPV/pertussis | 2.1 (2024) | 1–2% | Vaccine R&D |
| Fabrazyme | 1.1+ | 0–1% | Pipeline funding |
| Plavix | ~1.0 | 0–1% | Low‑effort cash |
Full Transparency, Always
Sanofi BCG Matrix
The file you're previewing on this page is the final Sanofi BCG Matrix you'll receive after purchase—no watermarks, no demo content, just a fully formatted, strategy-ready report built for clarity and professional use.
Dogs
Aubagio (Teriflunomide)
Aubagio (teriflunomide) is squarely in Sanofi’s Dog quadrant after generics entry in 2019–2021 drove U.S. net sales down from about €600m in 2016 to roughly €50–75m by 2024, eroding market share in oral MS.
The oral multiple sclerosis market is mature with 5+ established oral agents; annual growth for legacy oral DMTs is near 0–2%, leaving little upside for Aubagio’s declining franchise.
Sanofi has cut promotion and listed Aubagio as a non-core, decline-stage asset; strategic options include divestment or phased withdrawal as patent-era revenue fades.
Lovenox (Enoxaparin Sodium)
Lovenox (enoxaparin sodium) sits as a low-growth product in Sanofi’s BCG matrix: the anticoagulant market is highly commoditized and dominated by low-cost biosimilars, cutting margins and volumes. Its EU/US combined sales fell below €1 billion in 2024, with market share down by roughly 40% versus 2015 levels, so it no longer drives strategic growth. Lovenox now acts as a cash trap, consuming management time and CAPEX without clear routes back to market leadership or high returns.
Myozyme (Alglucosidase Alfa)
Myozyme (alglucosidase alfa) is classified as a Dog after Sanofi shifted patients to Nexviazyme, driving a 20% fall in annual sales to roughly €220m in 2024 from ~€275m in 2023.
It sits in a low-growth Pompe disease niche with shrinking market share as Sanofi cannibalizes Myozyme to protect its rare-disease franchise centered on Nexviazyme.
Expensive turnarounds are not viable; management is extracting remaining lifecycle value while limiting capex and marketing spend to preserve ~€50–70m EBITDA run-rate.
Cerezyme (Gaucher Disease)
Cerezyme (imiglucerase) is a legacy enzyme replacement for Gaucher disease whose market share has stagnated and declined versus newer oral eliglustat and other injectables; annual sales fell below €800m in 2024, down ~20% from 2019 levels, so it no longer drives Sanofi Rare Disease growth.
It is a prime portfolio-streamlining candidate as Sanofi shifts to first-in-class investments, freeing ~€200–€300m in operating margin to reallocate to novel gene/precision therapies.
- 2024 sales: <€800m
- 5-year decline: ~20% (2019–2024)
- Competitive threats: eliglustat (oral), newer ERTs
- Strategic move: divest/phase-out to fund first-in-class R&D
Aprovel/Avapro (Irbesartan)
Aprovel/Avapro (irbesartan) is a classic Dog for Sanofi: an established ARB in a genericized, low-growth antihypertensive market, with global sales under $200m in 2024 and single-digit margins versus double-digit for specialty drugs.
It contributes minimally to Sanofi’s strategic goals; Sanofi has been streamlining such assets since 2022 to reallocate ~€1.5bn R&D and capex toward its immunology pipeline.
- Genericized market: global antihypertensive growth ~1% (2024)
- Sales: <€200m (2024 estimate)
- Margins: low single digits vs specialty ~20%+
- Portfolio action: included in 2022–25 streamlining to free ~€1.5bn
Divest low-growth "Dogs" (Aubagio, Lovenox, Myozyme, Cerezyme, Aprovel) to fund specialty R&D
Dogs: Aubagio, Lovenox, Myozyme, Cerezyme, Aprovel—low growth, declining sales (Aubagio €50–75m; Lovenox <€1bn; Myozyme ~€220m; Cerezyme <€800m; Aprovel <€200m in 2024), reduced market share, low margins; recommended divest/phase-out to reallocate ~€200–€1.5bn to specialty R&D.
| Product | 2024 sales | 5y trend | Action |
|---|---|---|---|
| Aubagio | €50–75m | −90% | Divest |
| Lovenox | <€1bn | −40% | Phase-out |
| Myozyme | €220m | −20% | Limit capex |
| Cerezyme | <€800m | −20% | Divest |
| Aprovel | <€200m | Stable/decline | Streamline |
Question Marks
Tolebrutinib (Multiple Sclerosis)
Tolebrutinib is a high-potential Question Mark for Sanofi in the growing multiple sclerosis (MS) market; global MS drugs sales hit about $25.4B in 2024 and are forecast to reach $33B by 2030, so upside is large.
Despite mixed Phase 3 2025 results for some indications, a successful filing for non-relapsing secondary progressive MS (NRSPMS) could make it a Star given NRSPMS unmet need and pricing power.
Current market share is zero; as of Q4 2025 Sanofi capitalized >$1.2B in BTK R&D and tolebrutinib burns hundreds of millions annually, so it's a high-stakes invest-or-exit choice for management.
Amlitelimab (Atopic Dermatitis)
Amlitelimab enters Phase 3 in 2025 as a Sanofi Question Mark in the immunology market, where global atopic dermatitis (AD) sales reached about $11.5B in 2024 and are projected 6–8% CAGR; it targets Dupixent (Regeneron/Sanofi) as successor or adjunct.
Early Phase 2 showed clinically meaningful reductions in Eczema Area and Severity Index; no market share yet, so Sanofi must fund costly Phase 3s—typical AD Phase 3 programs cost $150–300M.
If Phase 3 proves superiority or differentiated safety, Amlitelimab could become a Star capturing multi-hundred-million to >$1B peak sales; failure risks a high-cost write-off and wasted R&D spend.
mRNA Seasonal Flu Vaccine (SP0237)
SP0237 sits in Sanofi’s Question Marks quadrant after the company in 2024 deprioritized its mRNA seasonal flu program, citing a tough U.S. market and estimated development costs above $1 billion to Phase 3; market for next-gen vaccines is projected to grow ~12% CAGR to 2030.
Sanofi’s mRNA share is minimal versus Moderna/Pfizer—Sanofi reported mRNA R&D spend of ~€400m in 2024—making SP0237 a risky bet; management is evaluating pivot to pandemic preparedness or full exit from seasonal mRNA.
Rilzabrutinib (Rare Diseases)
Rilzabrutinib is a Question Mark: under regulatory review for immune thrombocytopenia (ITP) and other rare diseases as of late 2025, targeting the oral BTK inhibitor market projected at ~$4.5B by 2030 and growing ~9% CAGR (2025–2030); current market share is zero and launch uptake is uncertain.
Sanofi must choose heavy global launch investment—estimated $200–400M upfront plus $50–100M annual marketing—to capture share, else slow adoption could relegate rilzabrutinib to a Dog.
- Regulatory status: under review late 2025
- Market size: oral BTK market ~$4.5B by 2030, ~9% CAGR
- Current share: 0%; launch cost est $200–400M
- Risk: low adoption → becomes a Dog
Frexalimab (Neuro-inflammation)
Frexalimab is an early-stage Question Mark in Sanofi’s neurology pipeline, a first-in-class anti-CD40L program targeting neuro-inflammation for autoimmune CNS disorders, addressing a market projected to grow ~8–10% CAGR to 2028 (~$25–30B for neuroimmunology-related therapies).
It is years from approval, generates zero revenue, and consumed tens-to-hundreds of millions in R&D by 2025; its path to Star hinges on pivotal-phase outcomes and Sanofi winning share in a crowded field of B-cell/T-cell and cytokine-targeting competitors.
- Novel MoA: anti-CD40L neuro-inflammation
- Market: high-growth, est $25–30B by 2028
- Financials: zero revenue; R&D spend likely $50–200M+ to date
- Key drivers: pivotal data, safety, differentiation vs B-cell/cytokine rivals
Sanofi's High-Risk R&D Bet: €1.6B Today for Multi‑Billion Market Hopes
Sanofi Question Marks: tolebrutinib, amlitelimab, SP0237, rilzabrutinib, frexalimab—zero current sales; combined 2024 R&D spend ~€1.6B; peak market opportunities: MS $25.4B (2024)->$33B (2030), AD $11.5B (2024), oral BTK ~$4.5B (2030), neuroimmunology $25–30B (2028); each needs $150–400M+ Phase 3/launch spend or risks write-off.
| Asset | Market 2024/2030 | R&D/Launch est |
|---|---|---|
| Tolebrutinib | MS $25.4B→$33B | $200–400M+ |
| Amlitelimab | AD $11.5B | $150–300M |